期刊文献+

100例HIV/AIDS患者接受AZT+3TC+EFV治疗不良事件的分析 被引量:6

Analysis of adverse events happened in 100 HIV/AIDS cases receiving AZT+3TC+EFV treatment
原文传递
导出
摘要 目的评价联合抗逆转录病毒药物治疗方案(AZT+3TC+EFV),治疗中国农村艾滋病病毒Ⅰ型(HIV-1)感染者的安全性。方法采取开放的、前瞻性的单组临床试验,观察100例受试者在52周抗病毒治疗过程中发生的不良事件(Adverse events,AE)。结果100例患者均出现至少1例次的AE,总共发生700例次,其中实验室检查异常、消化系统和神经系统AEs的发生率分别是42.15%、19.29%和14.14%,占所有AE的一半以上。最常见的是头昏,其次分别是血钾降低、丙氨酸转氨酶(ALT)增高,恶心和天冬氨酸转氨酶(AST)增高。在所有AE中,达到3级或4级的共有53例次,占7.57%(53/700)。其中血红蛋白降低和ALT/AST增高是最常见的AE。因发生严重不良事件(Serious adverse events,SAE)而退出研究的有13例(13%),其中有9例评定为与4级SAE很可能相关,其他可能无关。在研究结束时,约77.43%的AE痊愈,4.71%的好转,但有17.86%的患者AE还持续存在,无死亡病例。在所有的700例次AE中,27例次(3.86%)、207例次(29.57%)和281例次(40.14%)分别被判定为肯定有关、很可能有关和可能有关。结论AZT+3TC+EFV治疗方案对中国农村HIV-1感染者治疗是安全的,在治疗过程中尤其要注意肝功能和血红蛋白的变化。 Objective To assess the safety of a potent combined antiretroviral therapy regimen, 3TC/ZDV + EFV, for the treatment of HIV-1 infected persons in a rural area of China. Method An open-labeled prospective single-arm clinical study was conducted to observe the adverse events in HIV-infected subjects who received 50 week long ART therapy and whose CD4 + count was〈350 cells/mm3. Result Of the 100 subjects,everyone experienced at least one episode of adverse event(AE), and a total of 700 adverse events occurred among them during the span of 52 weeks. The rates of adverse events related to laboratory abnormal parameters, gastrointestinal disorders and nervous system were 42. 15 % (295), 19. 290//00 (135)and 14.14% (99), respectively, accounting for more than half of the overall cases/episodes of AEs. The most frequent symptoms were dizziness, followed by hypokalemia,increased ALT,nausea and raised AST. Of the total AEs 53 events/cases were assessed as grade 3 or 4 accounting for 7.57% (53/700) ,among which decreased hemoglobin and increased ALT/AST were the commonest manifestations. Thir- teen cases(13 %)withdrew from the study because of severe adverse events, of whom 9 cases were certainly due to 4 grade adverse events. At the end of the study, of the total AE cases 77.43% recovered, 4.71% improved, but 17.86% remained abnormal, None of the subjects died in the period of the study. Among all the 700 cases/episodes of AEs,27(3.86%) ,207(29.57%)and 281(40.14%)were assessed as definitely related,most likely related and likely related with the therapy, respectively. Conclusion The combined ART regimen was safe for the treatment of HIV-1 infected persons in a rural area of China. Monitoring the liver functions and hemoglobin during the therapeu- tic process should be given special attention.
出处 《中国艾滋病性病》 CAS 2009年第3期215-218,共4页 Chinese Journal of Aids & STD
基金 美国国立卫生院资助中国综合性艾滋病研究项目子项目
关键词 抗遗转录病毒治疗 AZT+3TC+EFV方案 不良事件 HAART Adverse Event (AE)
  • 相关文献

参考文献2

二级参考文献14

  • 1Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med, 1998,339:405-406.
  • 2Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 1997,337:734-739.
  • 3Cao Y, Ho DD, Todd J, et al. Clinical evaluation of Branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses, 1995, 11:353-361.
  • 4Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis, 1999, 179:527-537.
  • 5Vittinghoff E, Scheer S, O′Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis, 1999, 179: 717-720.
  • 6Tubiana R, Carcelain G, Mohand HA, et al. Immunologic reconstruction after antiretroviral treatment. Presse Med, 1999, 28:424-428.
  • 7Furtado MR, Callaway DS, Phair LP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med , 1999, 340: 1614-1622.
  • 8Poggi C, Profizi N, Djediouane A, et al. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection. AIDS, 1999, 13: 1213-1220.
  • 9Lodenyo H,Schoub B,Ally R,et al.Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital,Johannesburg[J].East Afr Med J,2000,77(1):13-15.
  • 10Den Brinker M,Wit FW,Wertheim-van Dillen PM,et al.Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection[J].AIDS,2000,22;14(18):2895-2902.

共引文献36

同被引文献48

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部